Congressional Health Care Caucus Policy Forum: Biosimilars: Moving Forward Under Health Care Reform Legislation (PPACA)

Monday, July 19, 2010 Indian Health News J E 4
ATTN: Healthcare Press

WHEN: TODAY, Monday, July 19 from 3 - 4 PM

WHERE: House Visitor Center Room 201 - U.S. Capitol Visitor's Center


Hosted by Rep. Michael C. Burgess, M.D., Chairman, Congressional Health Care Caucus

Contact: Dr. Merrill Matthews Jr. at +1-972-874-5139

/PRNewswire-USNewswire -- July 19/

-- Merrill Matthews, Institute for Policy Innovation -- Dr. Craig Kessler, Professor of Medicine and Pathology, Georgetown University -- Dr. Marc Cohen, Chief of the Division of Cardiology, Newark Beth Israel Medical Center, Professor of Medicine at Mount Sinai School of Medicine in New York City

SOURCE Institute for Policy Innovation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Biosimilars in India

Though biosimilars are highly valued for their effectiveness as treatments, the costs-per-patient of many biologics are often significant and sometimes can be prohibitive. As all countries tussle with the issues of access to biologics and other medicines while confronting increasingly limited health care resources; achievement of the full potential of biosimilars is becoming increasingly challenging. My colleagues and I recently authored, What we believe to be, one of the most in-depth reports on the Biosimilars industry in India. If anyone is interested in this, feel free to write to me at Ashritha.
Utah Conference 'Explosion of Youth Problems--Cris...
New Product Planning Plays a Critical Role for Fut...